Mandate

Vinge has advised Byggfakta in connection with its listing on Nasdaq Stockholm

The first day of trading on Nasdaq Stockholm large cap was 15 October 2021. The offer price was SEK 75 per share, equivalent to a market value for the Byggfakta Group of approximately SEK 16.4 billion. The offer covers 64,483,197 shares together with an oversubscription option to a total value of approximately SEK 5.5 billion.

Byggfakta Group, with its registered office in Ljusdal, Sweden, and dating back to 1936, is a leading digital platform which offers solutions which match actors in the building industry’s value chain, maximizes sales and improves efficiency for its customers.

Vinge’s team primarily consisted of Anders Strid, Rikard Lindahl, Edin Agic, Lina André, Linus Adolfsson, David Bokliden, Adrian Filipovic and Jacob Benzow (Capital Markets and Public M&A), Magnus Pauli (M&A), Albert Wållgren, Linn Adelwald, Ludvig Wettergren (Banking and Finance), Maria Schultzberg, Victor Ericsson and Emelie Svanberg (Tax), Anna-Maria Lagerqvist Gahm, Anna Högsten and Stina Karinsdotter (IP/IT), Rebecka Hansson (Employment) and Viktoria Owetz Leyva and Nathalie Hughes (VDR).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024